Last €2.01 EUR
Change Today -0.008 / -0.40%
Volume 508.4K
As of 11:30 AM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

sorin spa (SRN) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/6/14 - €2.35
52 Week Low
10/15/14 - €1.63
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SORIN SPA (SRN)

Related News

No related news articles were found.

sorin spa (SRN) Related Businessweek News

No Related Businessweek News Found

sorin spa (SRN) Details

Sorin S.p.A. develops, produces, and distributes medical devices for cardiac surgery and for the treatment of cardiac rhythm dysfunctions. It offers disposable biomedical devices and systems, including heart-lung machines; cardiopulmonary systems, such as oxygenators and custom packs; autotransfusion systems and disposables; perfusion tubing systems; cannulae; and endoscopic vessel harvesting systems for extracorporeal circulation during surgery. The company also provides mechanical heart valves, tissue heart valves, self-anchoring tissue heart valves, and annuloplasty rings to replace or repair dysfunctional heart valves or treat congenital diseases. In addition, it offers implantable devices, monitoring systems, and accessories to treat cardiac rhythm dysfunctions that comprise pacemakers, implantable defibrillators, systems to treat heart failure (CRT-D), programmers, electrodes, electrophysiology leads, and Holter monitors; and disposable medical devices for urology, urodynamics, heart surgery, and haemodialysis. The company sells its products worldwide primarily under the Sorin Biomedica, Dideco, Stöckert, Cobe Cardiovascular, Ela Medical, and Carbomedics brand names. Sorin S.p.A. was founded in 2004 and is headquartered in Milan, Italy.

3,733 Employees
Last Reported Date: 04/30/14
Founded in 2004

sorin spa (SRN) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: €789.0K
Chairman, President and Chairman of Executive...
Total Annual Compensation: €629.0K
Compensation as of Fiscal Year 2013.

sorin spa (SRN) Key Developments

Sorin Group Announces FDA Clearance and First U.S. Implant of Memo 3D ReChord Annuloplasty Ring

Sorin Group announced the U.S. Food and Drug Administration (FDA) clearance for Memo 3D ReChord™, an innovative semi-rigid annuloplasty ring for mitral valve repair. The new Memo 3D ReChord, Sorin Group’s latest innovation in mitral valve repair, incorporates an innovative chordal guide system into the existing Memo 3D ring to simplify and standardize the approach to artificial chord replacement. Memo 3D ReChord’s unique design streamlines mitral repair procedures while allowing surgeons to obtain reproducible results even in advanced chordal reconstructions. Memo 3D ReChord‘s one-of-its-kind features include: A unique temporary chordal guide system that simplifies artificial chord replacement. Sorin's exclusive Carbofilm™ coating to enhance hemo-compatibility. Innovative cell-structure design to accommodate the mitral saddle shape while enabling the physiological 3D motion of the native annulus.

Sorin SpA Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 11:20 AM

Sorin SpA Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 11:20 AM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom.

Sorin S.p.A. Announces Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Full Year 2014

Sorin S.p.A. announced consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company’s revenues were EUR 183.5 million, up 2.2% compared to the third quarter of 2013. EBITDA was EUR 28.1 million, or 15.3% of revenues, compared to EUR 32.1 million, or 17.8% of revenues in the third quarter of 2013, reflecting the negative impact of foreign exchange and continuous investments in growth initiatives. EBIT was EUR 14.5 million compared to EUR 19.4 million in the third quarter of 2013. Net profit was EUR 9.7 million compared to EUR 14.0 million in the third quarter of 2013. Adjusted net profit was EUR 11.7 million compared to EUR 15.5 million in the third quarter of 2013. Net financial debt as of September 30, 2014 was EUR 113.2 million compared to EUR 109.4 million as of June 30, 2014. Free cash flow was EUR 7.4 million. For the nine months, the company reported revenues up 2.8% to EUR 550.4 million, EBITDA of EUR 83.5 million or 15.2% of revenues (16.4% in the same period of 2013) and Adjusted Net profit of EUR 34.1 million or 6.2% of revenues (6.9% in the same period of 2013). The company estimates a negative impact on annual revenues of approximately EUR 5 million for the temporary production capacity limitation of Perceval and confirms 2014 Adjusted Net profit full-year guidance between EUR 55-60 million.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SRN:IM €2.01 EUR -0.008

SRN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Edwards Lifesciences Corp $129.63 USD -0.71
Getinge AB kr182.20 SEK -1.60
Greatbatch Inc $50.10 USD +1.00
InspireMD Inc $0.75 USD -0.0113
Stentys €5.26 EUR -0.11
View Industry Companies

Industry Analysis


Industry Average

Valuation SRN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow 9.1x
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SORIN SPA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at